Preclinical and phase 1 clinical safety of Setarud (IMOD™), a novel immunomodulator

Daru

Volumn 17, Issue 3, 2009, Pages 148-156

  Khairandish, P ^a   Mohraz, M ^a   Farzamfar, B ^b   Abdollahi, M ^c   Shahhosseiny, M H ^d   Madani, H ^e   Sadeghi, B ^f   Heshmat, R ^c   Gharibdoust, F ^c   Khorram Khorshid, H R ^g,h  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e Rabe Rashidi Institute Iran   (Iran)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^h AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Acute toxicity; Chronic toxicity; IMOD ; Maximum tolerated dose; Setarud

Indexed keywords

IMMUNOMODULATING AGENT; IMOD; SETARUD; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; EMBRYO; FEMALE; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETHAL DOSE; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OSSIFICATION; PHASE 1 CLINICAL TRIAL; TOXICITY TESTING;

EID: 70350339309     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Novitsky YA, Madani H, Gharibdoust F, Farhadi M, Farzamfar B, Mohraz M. EU Patent Application 087825, 2007.
2. Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. World J Gastroenterol 2005; 11: 6684-6688 (Pubitemid 43072712)
3. Schinella GR, Giner RM, Mordujovich BP, Rhos JL. Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 1998; 50: 1069-1074
4. Karata SD, Arda N, Candan A. Some medicinal plants as immunostimulant for fish. J Ethnopharmacol 2003; 88(1): 99-106. (Pubitemid 36945356)
5. Foster S, Duke JA. A Field Guide to Medicinal Plants; Eastern and Central N. America, Boston. Houghton Mifflin Co., 1990.
6. Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Phytomedicine 2007; 14: 568-579
7. Abdollahi M, Rahmat-Jirdeh N, Soltaninejad K. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Hum Exp Toxicol 2001; 20: 28-33. (Pubitemid 32372414)
8. Look MP, Rockstroh JK, Rao GS, Barton S, Lemoch H, Kaiser R, Kupfer B, Sudhop T, Spengler U, Sauerbruch T. Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur J Clin Invest 1998; 28(5):389-399 (Pubitemid 28261223)
9. Ogunro PS, Ogungbamigbe TO, Elemie PO, Egbewale BE, Adewole TA. Plasma selenium concentration and glutathione peroxidase activity in HIV-1/AIDS infected patients: a correlation with the disease progression. Niger Postgrad Med J 2006; 13(1): 1-5.
10. Rayman MP. The importance of selenium to human health. Lancet 2000; 356: 233-241.
11. Wilber CG. Toxicology of selenium: a review. Clin Toxicol 1980; 17: 171-230.
12. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-871.
13. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci 2003; 57(1):16-21. (Pubitemid 39663088)
14. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. MJA 2007; 186(3):146-151. (Pubitemid 46331200)
15. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E, Vernazza PL, Rickenbach M, Telenti A. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 2007; 12: 1157-1164
16. Nunez MJ, Martin-Carbonero L, Moreno V, Valencia E, Garcia-Samaniego J, Castillo JG, Barreiro P. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22(9):825-829 (Pubitemid 44757156)
17. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Markowitz M. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16(11):1511-1519 (Pubitemid 34804216)
18. Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V. Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol 2002; 40(10):3865-3866.
19. Yerly S, von Wyl V, Boni J, Schupbach J, Burgisser P, Klimkait T, Rickenbach M, Ledergerber B, Kaiser L, Günthard HF, Perrin L. Swiss HIV Cohort Study: Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Aids 2007; 21:2223-2229. (Pubitemid 350287221)
20. Schwartlander B, Stover J, Walker N, Bollinger L, Gutierrez JP, McGreevey W, Opuni M, Forsythe S, Kumaranayake L, Watts C, Bertozzi S. Resource Needs for HIV/AKDS. Science 2001; 292:2434-2436.
21. Hunt PW, Deeks GG. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J infect Dis 2006; 194: 1632-1634.
22. Imami N, Hardy G, Gotch F. Development of immunotherapeutic strategies for HIV-1 Expert Opin Biol Ther 2001; 1: 803-816
23. Imami N, Westrop S, Cranage A, Burton C, Gotch F. Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy. Future HIV Therapy 2007; 1: 171-179.
24. Khorram-Khorshid HR, Abdollahi M, Novitsky YA, Shahhosseiny MH, Sadeghi B, Madani H, Rahimi R, Farzamfar B. Studies on potential mutagenic and genotoxic activity of Setarud. Daru 2008; 16(4): 223-228.
25. Khorram-Khorshid HR, Azonov JA, Novitsky Y, Shahhosseiny MH. Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats. Ind J Gastro 2008; 27:110-112.
26. Azonov JA, Khorram Khorshid HR, Novitsky YA, Farhadi M, Ghorbanoghli Z, Shahhosseiny MH. Protective effects of setarud (IMODTM) on development of diet-induced hypercholesterolemia in rabbits. Daru 2008; 16(4): 218-222.
27. LeBlanc GA. Acute Toxicity. In: Hodgson E. A Textbook of Modern Toxicology. JOHN WILEY & SONS INC., New Jersey, 2004; pp: 215-224.
28. Dawson AB. A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain Technol 1926; 1: 123-124
29. Wilson JG.. Method for the administration agent and detecting malformation in experimental animals. In: Wilson JG, Work J. Teratology: Principles and Techniques, University of Chicago Press, Chicago, 1965.
30. NCI CTEP Help Desk. Common Toxicity Criteria Manual. 1999, June 1. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ ctcmanual-v4-10-4-99.pdf.
31. Food and Drug Administration. Toxicity and Adverse Events. http://www.fda.gov/Drugs/ accessed September 1, 2009.
32. Ferm VH, Hanlon DP, Willhite CC, Choy WN, Book SA. Embryotoxicity and dose-response relationships of selenium in hamsters. Reprod Toxicol 1990; 4: 183-190
33. Chow SC, Lin JP. Design and Analysis of Clinical Trials. Wiley-Interscience Publishing, New Jersey, 2004; pp: 215-238.
34. Ivanova A. A new dose-finding design for bivariate outcomes. Biometrics 2003; 59, 1001-1007 (Pubitemid 38021229)
35. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statist Med 2002; 21:2757-2770 (Pubitemid 35049343)
36. O' Quigley J. Continual Reassessment Method. In: Crowley J. Handbook of Statistics in Clinical Oncology. Marcel Dekker, New York, 2001; PP: 35-72.